Gary W. Pace PhD
Dr. Pace is a seasoned biopharmaceutical executive with over 30 years of experience in the industry. He has co-founded a number of early stage life science companies where he built products from the laboratory to commercialization.
Dr. Pace is currently founder, Director and Consultant of QRxPharma Ltd (ASX: QRX). He is also a Director of ResMed Inc (NYSE: RMD), Transition Therapeutics Inc (TSX: TTH), Celsion Corp (NASDAQ: CLN) and Peplin Limited (ASX: PEP). Dr. Pace is an elected Fellow of the Australian Academy of Technological Sciences and Engineering, author and co-author of over 50 research papers, reviews, and patents. In 2003, Dr. Pace was awarded a Centenary Medal by the Australian Government for service to Australian society in research and development. Dr. Pace holds a Bachelor of Science (Honors) from the University of New South Wales and a Ph.D. from MIT, where he was a Fulbright Scholar.